Head to Head Contrast: Metagenomi (NASDAQ:MGX) vs. Cumberland Pharmaceuticals (NASDAQ:CPIX)

Metagenomi (NASDAQ:MGX) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Metagenomi and Cumberland Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1	0	3	1	2.80
Cumberland Pharmaceuticals	1	0	0	0	1.00

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 650.00%. Given Metagenomi’s stronger consensus rating and higher probable upside, equities analysts clearly believe Metagenomi is more favorable than Cumberland Pharmaceuticals.

Institutional & Insider Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Metagenomi has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.

Profitability

This table compares Metagenomi and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Earnings and Valuation

This table compares Metagenomi and Cumberland Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21 million	1.79	-$87.87 million	($2.30)	-0.52
Cumberland Pharmaceuticals	$44.52 million	1.92	-$2.84 million	($0.49)	-11.67

Cumberland Pharmaceuticals has higher revenue and earnings than Metagenomi. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Summary

Cumberland Pharmaceuticals beats Metagenomi on 9 of the 15 factors compared between the two stocks.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.